Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 27

1.

Ligands for mapping alphavbeta3-integrin expression in vivo.

Schottelius M, Laufer B, Kessler H, Wester HJ.

Acc Chem Res. 2009 Jul 21;42(7):969-80. doi: 10.1021/ar800243b.

PMID:
19489579
2.

Radiolabelled RGD peptides and peptidomimetics for tumour targeting.

Haubner R, Decristoforo C.

Front Biosci (Landmark Ed). 2009 Jan 1;14:872-86. Review.

PMID:
19273105
3.

Integrins: the keys to unlocking angiogenesis.

Silva R, D'Amico G, Hodivala-Dilke KM, Reynolds LE.

Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1703-13. doi: 10.1161/ATVBAHA.108.172015. Epub 2008 Jul 24. Review.

4.

Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692.

Bach-Gansmo T, Bogsrud TV, Skretting A.

Clin Physiol Funct Imaging. 2008 Jul;28(4):235-9. doi: 10.1111/j.1475-097X.2008.00801.x. Epub 2008 Jul 1.

PMID:
18384623
5.

99mTc-NC100692--a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation.

Edwards D, Jones P, Haramis H, Battle M, Lear R, Barnett DJ, Edwards C, Crawford H, Black A, Godden V.

Nucl Med Biol. 2008 Apr;35(3):365-75. doi: 10.1016/j.nucmedbio.2007.11.010.

PMID:
18355693
6.

Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET.

Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M.

J Nucl Med. 2008 Feb;49(2):255-9. doi: 10.2967/jnumed.107.045526. Epub 2008 Jan 16.

7.

Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.

Beer AJ, Lorenzen S, Metz S, Herrmann K, Watzlowik P, Wester HJ, Peschel C, Lordick F, Schwaiger M.

J Nucl Med. 2008 Jan;49(1):22-9. Epub 2007 Dec 12.

8.

[18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck.

Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M.

Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6.

9.

NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging.

Indrevoll B, Kindberg GM, Solbakken M, Bjurgert E, Johansen JH, Karlsen H, Mendizabal M, Cuthbertson A.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6190-3. Epub 2006 Sep 26.

PMID:
17000103
10.

Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.

Bach-Gansmo T, Danielsson R, Saracco A, Wilczek B, Bogsrud TV, Fangberget A, Tangerud A, Tobin D.

J Nucl Med. 2006 Sep;47(9):1434-9. Erratum in: J Nucl Med. 2007 Apr;48(4):567.

11.

Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.

Beer AJ, Haubner R, Sarbia M, Goebel M, Luderschmidt S, Grosu AL, Schnell O, Niemeyer M, Kessler H, Wester HJ, Weber WA, Schwaiger M.

Clin Cancer Res. 2006 Jul 1;12(13):3942-9.

12.

Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients.

Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, Weber WA, Schwaiger M.

J Nucl Med. 2005 Aug;46(8):1333-41.

13.

Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia.

Hua J, Dobrucki LW, Sadeghi MM, Zhang J, Bourke BN, Cavaliere P, Song J, Chow C, Jahanshad N, van Royen N, Buschmann I, Madri JA, Mendizabal M, Sinusas AJ.

Circulation. 2005 Jun 21;111(24):3255-60. Epub 2005 Jun 13.

14.

Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.

Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M.

PLoS Med. 2005 Mar;2(3):e70. Epub 2005 Mar 29.

15.

Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies.

Haubner R, Wester HJ.

Curr Pharm Des. 2004;10(13):1439-55. Review.

PMID:
15134568
16.

Integrins: roles in cancer development and as treatment targets.

Jin H, Varner J.

Br J Cancer. 2004 Feb 9;90(3):561-5. Review.

17.

Targeted delivery of mutant Raf kinase to neovessels causes tumor regression.

Hood JD, Cheresh DA.

Cold Spring Harb Symp Quant Biol. 2002;67:285-91. Review. No abstract available.

PMID:
12858551
18.

Alpha(v)beta(3) integrin in angiogenesis and restenosis.

Kerr JS, Mousa SA, Slee AM.

Drug News Perspect. 2001 Apr;14(3):143-50.

PMID:
12819820
19.

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.

Kumar CC.

Curr Drug Targets. 2003 Feb;4(2):123-31. Review.

PMID:
12558065
20.

alphav Vitronectin receptors in vascular-mediated disorders.

Mousa SA.

Med Res Rev. 2003 Mar;23(2):190-9. Review.

PMID:
12500288

Supplemental Content

Support Center